RICHMOND, British Columbia, May 13, 2005 (PRIMEZONE) -- BioCurex (Pink Sheets:BOCX) is pleased to notify its shareholders that an online interview with the Company is available on AudioStocks.com, a financial information portal. The discussion reviews the corporate initiatives for the upcoming months, which includes further licensing of its blood tests to detect cancer. Further, using their validated RECAF technology, the company plans to refine the ability to image the locations of cancers in the body as well as advance the therapeutic applications.
BioCurex recently announced a significant licensing agreement with a global healthcare company for a selection of diagnostic applications of its patented/proprietary RECAF technology.
To listen to the interview, visit http://www.audiostocks.com/.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types, but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com.
Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.